TP53 and non-small cell lung carcinoma: Lastly, TP53 concomitant mutations might be a poor prognostic factor for patients treated with Gefitinib, and the complexity of identifying TP53 mutations may contribute to the efficacy and prognosis of molecular targeted therapy in NSCLC.